Prestige Consumer Healthcare (PBH) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Q4 2026 results expected May 13: Prestige is projected to report Q4 results before the open on May 13 with consensus estimates of $1.39 EPS and $293.76M revenue, and it has set FY2026 guidance at 4.540 EPS.
• Recent quarter missed estimates: In the prior quarter (reported Feb. 5) the company posted $1.14 EPS vs. $1.16 expected and $283.44M in revenue (down 2.4% YoY); analysts see about $5 EPS for the current and next fiscal year.
• Stock and ownership snapshot: PBH has a $2.61B market cap, a ~14.6 P/E, a 52‑week range of $51.24–$89.37, a consensus "Hold" rating (avg target $76.50), an insider sale of 1,000 shares, and roughly 99.95% institutional ownership.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is projected to issue its Q4 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $1.39 per share and revenue of $293.76 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Individuals can check the company's upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm's revenue was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.22 EPS. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

PBH stock traded down $0.64 during mid-day trading on Wednesday, reaching $55.11. The company's stock had a trading volume of 22,311 shares, compared to its average volume of 455,648. The stock has a market cap of $2.61 billion, a PE ratio of 14.59, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The company's 50 day moving average is $60.83 and its two-hundred day moving average is $62.03.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares of the company's stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.40% of the company's stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. boosted its position in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company's stock worth $26,000 after purchasing an additional 219 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after purchasing an additional 269 shares during the period. Danske Bank A S purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $37,000. Brown Brothers Harriman & Co. purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $44,000. Finally, CIBC Private Wealth Group LLC boosted its position in shares of Prestige Consumer Healthcare by 142.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company's stock worth $69,000 after purchasing an additional 647 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating for the company in a report on Friday, January 30th. Weiss Ratings reiterated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $76.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.